GlcAT-S CRISPR/Cas9 KO Plasmid (h): sc-408633
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- GlcAT-S CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the GlcAT-S genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
GlcAT-S CRISPR/Cas9 KO Plasmid (h) | sc-408633 | 20 µg | $397.00 |
Overview
B3GAT2 encodes glucuronyltransferase S (GlcAT-S), a Golgi-resident glycosyltransferase that transfers glucuronic acid to specific carbohydrate acceptors during glycan maturation. This activity contributes to the biosynthesis and remodeling of cell-surface and extracellular matrix glycoconjugates, influencing glycoprotein processing, proteoglycan-associated carbohydrate structures, and broader glycosylation-dependent signaling and adhesion programs. By shaping glycan composition, GlcAT-S can modulate receptor organization, cell–cell interactions, and matrix binding events that are central to tissue homeostasis and cellular differentiation. Dysregulated glycosylation pathways involving B3GAT2 have been investigated in the context of altered cell communication and stress responses relevant to multiple disease-associated phenotypes.
GlcAT-S CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the B3GAT2 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the B3GAT2 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the B3GAT2 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish GlcAT-S protein expression.
This CRISPR knockout system enables efficient generation of B3GAT2-deficient cell models for investigation of GlcAT-S signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting B3GAT2 exon(s) critical for GlcAT-S function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple B3GAT2 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by GlcAT-S CRISPR/Cas9 KO Plasmid (h) and GlcAT-S CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the B3GAT2 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by GlcAT-S HDR Plasmid (h) and GlcAT-S HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by B3GAT2 homology arms to support homology-directed repair at defined B3GAT2 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.